Viewing data from:

CEFPROZIL

ANDA

CEFPROZIL | A065208 | TEVA PHARMACEUTICALS USA INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 2 NDCs

Highest NADAC/Unit

$0.9066

per ea

Lowest NADAC/Unit

$0.4907

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00093107853CEFPROZIL 500 MG TABLET	$0.9066	EA	Generic	—	2026-10-21
00093107701CEFPROZIL 250 MG TABLET	$0.4907	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain6 active DMFs7 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

ORCHID PHARMA LTDCEFPROZIL

DMF 173752004

LUPIN LTDCEFPROZIL USP

DMF 177312004

APITORIA PHARMA PRIVATE LTDCEFPROZIL USP

DMF 184692005

PURE AND CURE HEALTHCARE PRIVATE LTDCEFPROZIL USP

DMF 240472010

QILU ANTIBIOTICS PHARMACEUTICAL CO LTDCEFPROZIL

DMF 266992013

COVALENT LABORATORIES PRIVATE LTDCEFPROZIL USP

DMF 293832015

SUN PHARMACEUTICAL INDUSTRIES LTDInactiveCEFPROZIL USP (NON-STERILE BULK)

DMF 169732003

SANDOZ PRIVATE LTDInactiveCEFPROZIL

DMF 174532004

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveCEFPROZIL

DMF 178272004

HETERO DRUGS LTDInactiveCEFPROZIL MONOHYDRATE

DMF 184342005

ORCHID CHEMICALS AND PHARMACEUTICALS LTDInactiveCEFPROZIL (PROCESS-2)

DMF 189012005

UNIMARK REMEDIES LTDInactiveCEFPROZIL USP

DMF 214712008

ACS DOBFAR SPAInactiveCEFPROZIL

DMF 263542012

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 250MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Dec 6, 2005

No patent or exclusivity listings for this strength.

#002 — 500MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Dec 6, 2005